Related Experiment Video
Updated: Nov 11, 2025
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Which novel agents will have a clinically meaningful impact in AML at diagnosis?
1Perelman School of Medicine at the University of Pennsylvania, Division of Hematology-Oncology, Abramson Cancer Center, Leukemia Program, Phiadelphia, PA, USA.
Abstract:
New drug approvals now afford AML physicians a wider choice of initial treatment options than ever before. Although chemotherapy for AML is by no means ready to be replaced entirely by novel agents, the role of traditional cytotoxics in AML therapy is rapidly changing. In particular, biologically targeted agents such as the BCL2 inhibitor venetoclax and inhibitors of FLT3 and IDH mutations stand out as drugs likely to take AML therapy in important new directions. Maximum response and survival benefits likely require combinations of novel agents and chemotherapy or multiple novel agents together. The recently-published phase 3 VIALE-A study demonstrates a very successful example of a new combination approach, which led to venetoclax plus azacitidine establishing itself as the new standard of care for patients unfit for intensive chemotherapy. One could reasonably expect other subsets of AML to benefit from this regimen or other applications of venetoclax combinations. Building on this experience, venetoclax-based regimens also have the potential to replace standard intensive cytarabine/anthracycline "7&3" induction approach for some if not many patients who are fit for induction. This review will describe novel agents with the greatest potential for impactful frontline applications that will change the AML treatment paradigm.
Insights
Novel targeted therapies, including BCL2 inhibitor venetoclax, are transforming acute myeloid leukemia (AML) treatment. Combinations of these agents with chemotherapy or other novel drugs offer new standards of care, especially for patients unfit for intensive chemotherapy.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Acute myeloid leukemia (AML) treatment is evolving with new drug approvals.
- Traditional chemotherapy's role is changing due to novel targeted agents.
- Venetoclax (BCL2 inhibitor) and FLT3/IDH inhibitors are key novel agents.
Purpose of the Study:
- To review novel agents with significant potential in frontline AML therapy.
- To discuss the changing AML treatment paradigm driven by targeted therapies.
- To highlight combinations of novel agents and chemotherapy for improved outcomes.
Main Methods:
- Review of recent clinical trial data, focusing on novel agents in AML.
- Analysis of combination strategies involving venetoclax, FLT3, and IDH inhibitors.
- Evaluation of the impact of novel agents on the AML treatment landscape.
Main Results:
- Venetoclax plus azacitidine is a new standard of care for AML patients unfit for intensive chemotherapy (VIALE-A study).
- Novel agents, particularly venetoclax combinations, show potential to replace intensive induction chemotherapy ('7&3') for some patients.
- Targeted therapies are driving significant shifts in AML treatment protocols.
Conclusions:
- Novel targeted agents are revolutionizing AML therapy, offering new treatment options.
- Combination therapies, especially those involving venetoclax, are crucial for maximizing response and survival benefits.
- The AML treatment paradigm is shifting towards personalized medicine with targeted agents.
Related Concept Videos
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...